Cancer immunotherapies targeting the PD1/PDL-1 axis have been approved by the FDA for the treatment of multiple types of tumors; they induce clinically durable responses and consequently extend overall progression-free survival [1, 3]. This evidence concerns the gene CD274 and cancer.